Emblem Corp EMMBF

RE:RE:RE:RE:Nice buying coming in...

[Buckshot26]

Fantastic post.  I don't think anyone is close to Emblem in the targeted drug or exact dosage mechanisms (which we must not forget) space.  Canopy could be interesting as well through their Canopy Health Innovations arm which they raise $7.1m specifically for. I have yet to read or hear anything much about how they plan to spend that moneybut I assume they are spending those funds on something along these lines.

Murmur13 wrote: Yeah, that is where I was kinda looking/thinking.

I am familiar with many patients that are either on Doctor prescribed cannabis for MS, movement disorders (Parkinson's, Dystonia, tremor, etc.), nerve pain disorders (fibromyalgia, carpal, lyme disease, etc.), or simply self-prescribe the various CBD oils. Unfortunately, there are real difficulties finding the right cannabis strain, CBD %, etc. for the individual. Solving that problem = $$$.

I anticipate that once the excitement of recreational purchasers, and the flood of opportunistic start-up companies fades, that the "serious" providers will realize the potential of providing specific formulas targeting the various medical conditions. Many of these potential end users will be the seniors and super seniors.....which is interesting because the largest demographic percent increase of cannabis products in Colorado since legalization was, I believe, senior's use of cannabis oils and edibles.

It might take 5 to 7 years, or less, but yes, specific formulas could be patented for pills or transdermal patches - which would then take a cannabis company to drug company status. That could be huge.

This is is why I am trying to research which companies have the probability/possibility of not just satisfying the recreational use market, but the fine chemical composure/demands of the drug market.  

Obviously, like the plethora of Internet companies tossed out in the early years of Internet, many cannabis companies will probably eventually fail by 2019 and on.

So it is due to John Stewart (from Purdue pharma) that I am on board with Emblem, as it, on the surface, appears to have that possible long term potential. If anyone has any observations of other cannabis companies that have potential to get serious about targeted drug formulations, please let me know. Serious only please....

Mur